| | Author | Year | Population | Intervention SLNB alone | Control completion ALND | Follow-Up | Overall survival | Disease free survival | Locoregional recurrence |
| | Bilimoria et al. [18] NCDB | 1998–2005 | SLNB positive —97,314; macroscopic —87,055; microscopic —10,259 | 20,217 Macroscopic —16,543 Microscopic-3,674 | 77,097; macroscopic —70,512; microscopic —6,585 | 63 months | Macroscopic, HR, 0.89, 95% CI, 0.76–1.04,
82.1 versus 81.8%,, ; microscopic, 90.3 versus 90.3%, ; no significant difference | Macroscopic,
89.9 versus 89.1%, , microscopic,
99 Versus 97.8%, ; no Significant difference | Macroscopic,
1.0 versus 1.2%, ; microscopic,
0.4 versus 0.2%, ; lower in ALND but not significant |
| | Yi et al. [19] SEER database | 1998–2004 | SLN Positive —26,986; macroscopic —20,146; microscopic 6,838 | 4,425 Macroscopic —2,185 Microscopic —2,240 | 22,561; macroscopic —17,963; microscopic —4,598 | 50 months | Macroscopic,
HR 1.2, 95% CI, 1.1–1.4;
overall no significant difference including microscopic SLN | Macroscopic,
HR 1.5, 95% CI, 1.3–1.8;
overall no significant difference including microscopic SLN | Microscopic,
0.2 V 0.08%, HR—0.30, ;
macroscopic: lower risk in ALND but not significant;
microscopic: no difference |
| | Galimberti et al. [20] | 1999–2007 | SLN microscopic —377 | 377 | None | 60 months | 97.3% (95% CI, 95.3–99.3) | Not mentioned | 2.4% (95% CI, 1.1–4.5) |
| | Guenther et al. [21] | 1996–2001 | SLN positive —46 | 46 | None | 32 months | 100% | 97.8% | None |
| | Spiguel et al. [22] | 1998–2009 | SLN positive —123 | 123 | None | 94.8 months | Not mentioned | 85% | 0.8% axillary, 1.7% breast recurrence |
|
|
